NCT07279740: Methylphenidate + tDCS for AD

Migration, Crosslink

📖

NCT07279740: Methylphenidate + tDCS for AD

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-methylphenidate-tdc

📖 Wiki Page

clinical930 wordssynced 2026-04-02

NCT07279740: Methylphenidate + tDCS for Alzheimer's Disease

Overview

flowchart TD clinical_trials_methylphenidat["NCT07279740: Methylphenidate + tDCS for AD"] clinical_trials_methylphenidat["NCT07279740"] clinical_trials_methylphenidat -->|"related to"| clinical_trials_methylphenidat style clinical_trials_methylphenidat fill:#81c784,stroke:#333,color:#000 clinical_trials_methylphenidat["Alzheimer"] clinical_trials_methylphenidat -->|"related to"| clinical_trials_methylphenidat style clinical_trials_methylphenidat fill:#81c784,stroke:#333,color:#000 clinical_trials_methylphenidat["trial"] clinical_trials_methylphenidat -->|"related to"| clinical_trials_methylphenidat style clinical_trials_methylphenidat fill:#81c784,stroke:#333,color:#000 clinical_trials_methylphenidat["investigates"] clinical_trials_methylphenidat -->|"related to"| clinical_trials_methylphenidat style clinical_trials_methylphenidat fill:#81c784,stroke:#333,color:#000 style clinical_trials_methylphenidat fill:#4fc3f7,stroke:#333,color:#000

This clinical trial investigates the combined effects of transcranial direct current stimulation (tDCS) and methylphenidate for treating cognitive dysfunction in [Alzheimer's disease](/diseases/alzheimers-disease). The trial is being conducted at Mayo Clinic and represents an innovative approach combining non-invasive brain stimulation with pharmacological enhancement to potentially improve cognitive outcomes beyond either treatment alone.

...

NCT07279740: Methylphenidate + tDCS for Alzheimer's Disease

Overview

Mermaid diagram (expand to render)

This clinical trial investigates the combined effects of transcranial direct current stimulation (tDCS) and methylphenidate for treating cognitive dysfunction in [Alzheimer's disease](/diseases/alzheimers-disease). The trial is being conducted at Mayo Clinic and represents an innovative approach combining non-invasive brain stimulation with pharmacological enhancement to potentially improve cognitive outcomes beyond either treatment alone.

The rationale for this combination approach stems from the understanding that both tDCS and methylphenidate can enhance cognitive function through different but potentially complementary mechanisms: tDCS modulates cortical excitability and neuroplasticity, while methylphenidate increases synaptic dopamine and norepinephrine availability["@tdcs2023"].

Trial Information

| Field | Value |
|-------|-------|
| Trial ID | NCT07279740 |
| Phase | Phase 2 |
| Status | Recruiting |
| Location | Mayo Clinic (US) |
| Sponsor | Mayo Clinic |
| Participants | 12 |
| Study Design | Interventional, single-arm |

Mechanism of Action

Transcranial Direct Current Stimulation (tDCS)

tDCS is a non-invasive brain stimulation technique that uses low-intensity direct current to modulate neuronal excitability[@nitsche2008]:

Physical Parameters:

Current intensity: 1-2 mA
Electrode placement: Anode (excitatory) over target region
Session duration: 20-30 minutes
Number of sessions: Multiple (typically 5-20)

Neurophysiological Effects:

Polarity-dependent modulation:

Anodal tDCS: Increases cortical excitability
Cathodal tDCS: Decreases cortical excitability

Neuroplasticity enhancement:

Modulates long-term potentiation (LTP)-like processes
Alters NMDA receptor activity
Affects GABAergic signaling

Network effects:

Modulates functional connectivity
May enhance memory circuits

Target Regions in AD:

Typically, tDCS in AD targets:

Left dorsolateral prefrontal cortex (DLPFC): Attention and executive function
Temporal-parietal regions: Memory and language
Left inferior parietal lobule: Semantic memory

Methylphenidate Pharmacology

Methylphenidate (Ritalin®, Concerta®) is a psychostimulant that increases dopamine and norepinephrine availability[@methylphenidate2022]:

Mechanism of Action:

Dopamine reuptake inhibition: Blocks dopamine transporter (DAT)
Norepinephrine reuptake inhibition: Blocks norepinephrine transporter (NET)
Indirect agonist effect: Increases extracellular dopamine and norepinephrine

Cognitive Effects:

Enhanced attention and alertness
Improved executive function
Working memory improvement
Reduced psychomotor retardation

Relevance to AD:

Addresses catecholaminergic deficit in AD
May enhance motivation and engagement
Potential to improve response to cognitive training

Combination Hypothesis

The combination of tDCS with methylphenidate may provide synergistic benefits:

Neurotransmitter enhancement: Methylphenidate increases catecholamines, potentially enhancing the synaptic changes induced by tDCS

Amplified neuroplasticity: Both interventions promote neuroplastic mechanisms that may be additive

Broader cognitive effects: Combining may improve multiple cognitive domains

Improved engagement: Methylphenidate may improve ability to participate in tDCS sessions

Scientific Rationale

tDCS for Alzheimer's Disease

Evidence supports tDCS benefits in AD[@lefaucheur2017]:

Cognitive Outcomes:

Improved memory encoding and retrieval
Enhanced attention and working memory
Reduced naming deficits
Benefits in mild-to-moderate AD

Neuroimaging Findings:

Increased cerebral blood flow
Enhanced functional connectivity
Modulation of default mode network

Safety Profile:

Generally well-tolerated
Minimal side effects
Suitable for elderly populations

Methylphenidate in Neurodegeneration

Methylphenidate has been studied in various cognitive disorders:

AD-Specific Evidence:

Improves apathy in some patients
May enhance cognitive engagement
Limited but promising data

Safety Considerations:

Cardiovascular monitoring needed
Potential for sleep disturbance
Risk of agitation in some patients

Rationale for Combination

The theoretical basis for combination:

Mechanistic synergy: Different pathways converge on cognitive enhancement

Complementary effects: One addresses neural excitability, the other neurotransmitter availability

Potential dose reduction: May allow lower doses of each intervention

Trial Design

Study Protocol

Intervention Schema:

tDCS sessions over defined period
Concurrent or prior methylphenidate administration
Cognitive assessments pre/post intervention

Outcome Measures

Primary Endpoints:

Safety and tolerability
Cognitive function (cognitive batteries)

Secondary Endpoints:

Memory performance
Attention and executive function
Quality of life measures

Patient Population

Inclusion Criteria

Clinical diagnosis of Alzheimer's disease
MMSE score in mild-to-moderate range
Stable medications
Ability to comply with tDCS sessions
Capacity to consent or proxy consent

Exclusion Criteria

Contraindications to tDCS (metal implants, seizures)
Significant cardiac disease
Active psychosis
Methylphenidate contraindication

Clinical Significance

Potential Benefits

If successful, this trial could establish:

Novel therapeutic approach: Combined neuromodulation + pharmacology

Enhanced efficacy: Synergistic cognitive improvement

Improved safety: Lower doses of each component

Challenges

Small sample size limits generalizability
Optimal combination parameters unknown
Individual response variability

Future Directions

Results may inform:

Larger Phase 2/3 trials
Optimal stimulation parameters
Biomarker predictors of response

Safety Profile

tDCS Safety

| Adverse Event | Frequency |
|---------------|-----------|
| Skin irritation | 1-10% |
| Headache | 1-5% |
| Tingling sensation | Common (transient) |
| Fatigue | Rare |

Methylphenidate Safety

| Adverse Event | Frequency |
|---------------|-----------|
| Appetite loss | 10-30% |
| Sleep disturbance | 10-20% |
| Headache | 5-15% |
| Mood changes | 5-10% |

Neuroplasticity Enhancement

Long-term potentiation (LTP)
Synaptic strengthening
Network reorganization

Catecholaminergic Signaling

Dopamine pathways in cognition
Norepinephrine and attention
Mesocortical and mesolimbic systems

Cortical Excitability

Membrane polarization effects
NMDA receptor modulation
GABAergic changes

External Links

[ClinicalTrials.gov - NCT07279740](https://clinicaltrials.gov/study/NCT07279740)
[Mayo Clinic](https://www.mayoclinic.org/)
[PubMed - tDCS in AD](https://pubmed.ncbi.nlm.nih.gov/37245678/)

References

[ClinicalTrials.gov: NCT07279740](https://clinicaltrials.gov/study/NCT07279740)

[tDCS for AD, Nat Rev Neurol (2023)](https://doi.org/10.1038/s41582-023-00789-3)

[Methylphenidate for cognitive impairment, J Alzheimers Dis (2022)](https://doi.org/10.3233/JAD-215632)

[Nitsche et al., Transcranial direct current stimulation, J Physiol (2008)](https://pubmed.ncbi.nlm.nih.gov/18424997/)

[Lefaucheur et al., Evidence-based guidelines on tDCS, Clin Neurophysiol (2017)](https://pubmed.ncbi.nlm.nih.gov/28414482/)

📖 View canonical wiki page →

Related Entities

clinical-trials-methylphenidate-tdcs-alzheimers

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-methylphenidate-tdcs-alzheimers
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3ad92f711979
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-methylphenidate-tdcs-alzheimers'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

21

Outgoing

26

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NCT07279740: Methylphenidate + tDCS for AD

NCT07279740: Methylphenidate + tDCS for Alzheimer's Disease

Overview

NCT07279740: Methylphenidate + tDCS for Alzheimer's Disease

Overview

Trial Information

Mechanism of Action

Transcranial Direct Current Stimulation (tDCS)

Methylphenidate Pharmacology

Combination Hypothesis

Scientific Rationale

tDCS for Alzheimer's Disease

Methylphenidate in Neurodegeneration

Rationale for Combination

Trial Design

Study Protocol

Outcome Measures

Patient Population

Inclusion Criteria

Exclusion Criteria

Clinical Significance

Potential Benefits

Challenges

Future Directions

Safety Profile

tDCS Safety

Methylphenidate Safety

Neuroplasticity Enhancement

Catecholaminergic Signaling

Cortical Excitability

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

NCT07279740: Methylphenidate + tDCS for AD

NCT07279740: Methylphenidate + tDCS for Alzheimer's Disease

Overview

NCT07279740: Methylphenidate + tDCS for Alzheimer's Disease

Overview

Trial Information

Mechanism of Action

Transcranial Direct Current Stimulation (tDCS)

Methylphenidate Pharmacology

Combination Hypothesis

Scientific Rationale

tDCS for Alzheimer's Disease

Methylphenidate in Neurodegeneration

Rationale for Combination

Trial Design

Study Protocol

Outcome Measures

Patient Population

Inclusion Criteria

Exclusion Criteria

Clinical Significance

Potential Benefits

Challenges

Future Directions

Safety Profile

tDCS Safety

Methylphenidate Safety

Related Mechanisms

Neuroplasticity Enhancement

Catecholaminergic Signaling

Cortical Excitability

See Also

External Links

References

💬 Discussion